Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| argenx SE | Efgartigimod - (ALKIVIA) | Myositis subsets (Immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM)) | Phase 2/3 | Data Released | Intravenous | Immunology |
| argenx SE | Efgartigimod - (UplighTED) | Thyroid eye disease (TED) | Phase 3 | Trial Discontinued | Intravenous | Opthalmic |
| argenx SE | Empasiprubart (ARGX-117) - (EMPASSION) | Multifocal motor neuropathy (MMN) | Phase 3 | Ongoing | Intravenous | Neurology |
| argenx SE | Empasiprubart (ARGX-117) - (EMPASSION) | Multifocal motor neuropathy (MMN) | Phase 3 | Ongoing | Intravenous | Neurology |
| argenx SE | Adimanebart | Amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) | Phase 2 | Ongoing | Oral | Neurology |
| argenx SE | Efgartigimod - (ALPHA) | COVID-19-mediated postural orthostatic tachycardia syndrome (POTS) | Phase 2 | Ongoing | Intravenous | COVID-19 |
| argenx SE | Cusatuzumab (ARGX-110) and VIDAZA (Azacitidine) - (CULMINATE) | Acute myeloid leukemia (AML) | Phase 2 | Trial Completed | Intravenous Subcutaneous | Oncology |
| Aridis Pharmaceuticals Inc. | Aerucin (AR-105) | Pseudomonas aeruginosa | Phase 2 | Intravenous | Antibiotic |
